The 36-month beta value for ACXP is also noteworthy at -1.37. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACXP is 20.39M, and at present, short sellers hold a 1.88% of that float. The average trading volume of ACXP on June 04, 2025 was 188.09K shares.
ACXP) stock’s latest price update
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) has experienced a decline in its stock price by -7.74 compared to its previous closing price of 0.38. However, the company has seen a fall of -11.68% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-13 that Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Robert Shawah – Co-Founder and CFO David Luci – President and CEO Conference Call Participants Joanne Lee – Maxim Group James Molloy – Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are in a listen-only mode.
ACXP’s Market Performance
Acurx Pharmaceuticals Inc (ACXP) has experienced a -11.68% fall in stock performance for the past week, with a -15.68% drop in the past month, and a -44.18% drop in the past quarter. The volatility ratio for the week is 3.85%, and the volatility levels for the past 30 days are at 5.14% for ACXP. The simple moving average for the past 20 days is -8.99% for ACXP’s stock, with a -68.28% simple moving average for the past 200 days.
ACXP Trading at -9.12% from the 50-Day Moving Average
After a stumble in the market that brought ACXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.53% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACXP starting from Scodari Joseph C, who purchase 24,631 shares at the price of $1.01 back on Jan 06 ’25. After this action, Scodari Joseph C now owns 27,708 shares of Acurx Pharmaceuticals Inc, valued at $25,000 using the latest closing price.
Sailer Carl, the Director of Acurx Pharmaceuticals Inc, purchase 24,631 shares at $1.01 during a trade that took place back on Jan 06 ’25, which means that Sailer Carl is holding 137,183 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for ACXP
The total capital return value is set at 0.0. Equity return is now at value -285.79, with -170.68 for asset returns.
Currently, EBITDA for the company is -14.1 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
In summary, Acurx Pharmaceuticals Inc (ACXP) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
